chloramphenicol has been researched along with Erythremia in 3 studies
Amphenicol: Chloramphenicol and its derivatives.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Potolsky, A | 1 |
| Creger, WP | 1 |
| Mathé, G | 1 |
| Amiel, JL | 1 |
| Schwarzenberg, L | 1 |
| Choay, J | 1 |
| Trolard, P | 1 |
| Schneider, M | 1 |
| Hayat, M | 1 |
| Schlumberger, JR | 1 |
| Jasmin, C | 1 |
| Rowley, JD | 1 |
| Blaisdell, RK | 1 |
| Jacobson, LO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment[NCT00065260] | Phase 2 | 54 participants (Actual) | Interventional | 2003-11-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with robust hematologic recovery with reticulocyte or platelet count ≥ 50,000/uL (NCT00065260)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| r-ATG /Cyclosporine | 9 |
| Alemtuzumab (Campath-1H) | 9 |
Percent of cumulative incidence of clonal evolution in participants to either paroxysmal nocturnal hemoglobinuria (PNH), myelodysplasia or acute leukemia. (NCT00065260)
Timeframe: 3 years
| Intervention | Percentage of Cumulative Incidence (Number) |
|---|---|
| r-ATG /Cyclosporine | 16 |
| Alemtuzumab (Campath-1H) | 5 |
Percentage of cumulative incidence of relapse of disease in participants (NCT00065260)
Timeframe: 3 year
| Intervention | percentage of cumulative incidence (Number) |
|---|---|
| r-ATG /Cyclosporine | 19 |
| Alemtuzumab (Campath-1H) | 9 |
Number of participants no longer meeting the criteria for severe aplastic anemia as measured by response to treatment at 6 months (NCT00065260)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| No Response | Partial Response | Complete Response | |
| Alemtuzumab (Campath-1H) | 17 | 9 | 0 |
| r-ATG /Cyclosporine | 18 | 9 | 0 |
Percentage of participants no longer meeting the criteria for severe aplastic anemia as measured by response to treatment (NCT00065260)
Timeframe: 3 months and 6 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 3 Months | 6 Months | |
| Alemtuzumab (Campath-1H) | 19 | 37 |
| r-ATG /Cyclosporine | 19 | 33 |
3 other studies available for chloramphenicol and Erythremia
| Article | Year |
|---|---|
Radiation and drug therapies, and leukemia.
Topics: Antineoplastic Agents; Benzene; Bone Marrow Diseases; Chloramphenicol; Cyclophosphamide; Dose-Respon | 1973 |
Bone marrow graft in man after conditioning by antilymphocytic serum.
Topics: Acute Disease; Adolescent; Adult; Agranulocytosis; Antilymphocyte Serum; Bone Marrow Transplantation | 1970 |
Chromosome studies in preleukemia. I. Aneuploidy of group C chromosomes in three patients.
Topics: Adult; Anemia; Anemia, Aplastic; Anemia, Sideroblastic; Chloramphenicol; Chromosome Aberrations; Chr | 1966 |